pproxim
million
red
cell
unit
million
platelet
transfus
singl
donor
apheresi
platelet
unit
rest
pool
usual
six
random
donor
platelet
unit
administ
unit
state
year
transfusionrel
advers
event
occur
transfus
seriou
advers
event
estim
less
transfus
earli
estim
indic
transfusionassoci
advers
event
could
lead
shortterm
ie
includ
diseas
transmissionrel
death
mortal
death
per
patient
approxim
transfusionrel
deathsyear
unit
state
recent
estim
suggest
transfusionrel
death
underreport
longterm
total
ie
includ
diseas
transmissionrel
death
mortal
probabl
closer
one
death
per
everi
platelet
red
cell
unit
administ
approxim
transfusionrel
death
per
year
unit
state
even
estim
howev
may
underestim
transfusionrel
mortal
exampl
transfusionrel
acut
lung
injuri
trali
relat
fatal
report
project
base
incid
transfus
mortal
rate
indic
syndrom
account
least
death
annual
unit
state
respect
lead
caus
death
report
food
drug
administr
fda
indic
trali
abo
blood
group
hemolyt
transfus
reaction
bacteri
contamin
platelet
account
transfusionrel
death
composit
risk
transmiss
lipidenvelop
virus
hiv
u
human
tlymphotrop
viru
htlviii
u
hepat
b
u
hepat
c
u
estim
u
substanti
declin
risk
transfusionrel
viral
transmiss
occur
past
year
relat
implement
donor
screen
test
strategi
improv
came
immunoassay
increas
sensit
recent
nucleic
acid
test
procedur
detect
viral
rnadna
window
period
fifti
percent
patient
acquir
hepat
c
viru
hcv
develop
liver
diseas
although
symptom
appar
within
week
month
patient
asymptomat
develop
cirrhosi
within
year
subsequ
develop
hepatocellular
carcinoma
contrast
transmiss
hepat
e
enter
form
hepat
rare
associ
chronic
infect
bloodborn
infecti
diseas
syphili
epsteinbarr
viru
leishmaniasi
lyme
diseas
brucellosi
parvoviru
increas
preval
hemophiliac
tickborn
enceph
viru
colorado
tick
fever
viru
sever
acut
respiratori
syndrom
sar
west
nile
viru
human
herp
virus
parasit
diseas
eg
malaria
babesiosi
toxoplasmosi
chaga
diseas
variant
creutzfeldtjakob
diseas
vcjd
transmit
mean
transfus
although
mani
agent
rare
blood
donor
unit
state
febril
nonhemolyt
transfus
reaction
nhtr
consist
fever
c
transfus
occur
red
cell
transfus
relat
one
sever
potenti
mechan
preform
cytokin
within
store
unit
host
antibodi
donor
ie
graft
lymphocyt
gener
selflimit
incid
febril
nhtr
may
decreas
perhap
use
prestorag
leukoreduc
blood
compon
reaction
often
prevent
pretreat
acetaminophen
although
estim
death
rate
relat
hiv
hepat
declin
death
relat
transfus
caus
sepsi
secondari
bacteri
contamin
platelet
estim
death
per
million
unit
transfus
platelet
concern
base
substanti
increas
use
platelet
transfus
unit
state
support
cardiac
surgeri
oncolog
peripher
blood
stem
cell
pbsc
transplant
program
infus
bacteri
contamin
blood
uncommon
caus
febril
transfus
reaction
occur
red
blood
cell
rbc
product
store
c
organ
often
yersinia
enterocolitica
much
higher
frequenc
platelet
store
c
ie
howev
lead
sepsi
patient
transfus
contamin
blood
associ
mortal
rate
addit
account
least
transfusionrel
fatal
previous
report
fda
bacteri
growth
commonli
occur
compon
store
room
temperatur
per
apheresi
platelet
unit
especi
storag
interv
greater
day
led
current
fda
limit
platelet
outdat
day
recent
fda
licens
system
storag
apheresi
platelet
day
bacteri
cultur
perform
product
releas
form
bacteri
qualiti
control
screen
perform
platelet
product
requir
method
sensit
cultur
system
transfus
bacteri
contamin
blood
suspect
patient
manifest
one
follow
symptom
complic
high
fever
chill
hemodynam
perturb
eg
tachycardia
hypotens
shock
gastrointestin
gi
symptom
eg
emesi
diarrhea
hemoglobinuria
dissemin
intravascular
coagul
dic
oliguria
transfus
unit
examin
sign
bacteri
contamin
eg
discolor
dark
color
bubbl
transfusionassoci
respiratori
distress
relat
one
follow
order
decreas
frequenc
fluid
overload
transfusionassoci
circulatori
overload
taco
allerg
reaction
trali
although
exact
incid
circulatori
overload
relat
transfus
unknown
eg
everi
u
like
older
patient
histori
congest
heart
failur
estim
preval
rate
trali
rang
u
u
transfus
platelet
u
u
red
blood
cell
rang
transfus
associ
circulatori
overload
taco
trali
reflect
clinic
difficulti
diagnosi
underreport
transfus
reaction
trali
occur
antihla
human
leukocyt
antigen
antihna
human
neutrophil
antigen
antibodi
commonli
observ
unit
multipar
donor
possibl
neutrophilactiv
lipid
mediat
within
transfus
unit
attack
circul
pulmonari
leukocyt
stimul
complement
activ
pulmonari
injuri
hypothesi
howev
explain
case
trali
twohit
hypothesi
propos
previous
first
event
involv
prime
neutrophil
underli
condit
eg
trauma
infect
surgeri
follow
infus
substanc
transfus
eg
antihla
antihna
antibodi
biolog
activ
lipid
lead
trali
syndrom
character
acut
hour
transfus
onset
sever
hypoxemia
bilater
noncardiogen
pulmonari
edema
tachycardiahypotens
fever
ventilatori
hemodynam
support
manag
patient
recov
within
hour
preval
trali
develop
acut
respiratori
compromis
transfus
advoc
much
common
recent
canadian
consensu
meet
fact
increas
report
fda
incid
tralirel
death
patient
develop
syndrom
may
much
higher
previous
thought
high
death
report
place
close
lead
caus
death
ie
acut
hemolyt
reaction
bacteri
contamin
platelet
analysi
recent
public
indic
syndrom
underreport
fatal
report
lowend
project
ie
incid
transfus
mortal
rate
indic
syndrom
account
mani
death
annual
unit
state
addit
trali
diagnos
correctli
treatment
patient
therapi
design
manag
cardiogen
pulmonari
edema
ie
diuret
administr
lead
advers
outcom
pathophysiolog
trali
still
elucid
uncertain
whether
mechan
expand
beyond
antihla
antihna
antibodi
lipid
mediat
understand
exact
role
transfus
develop
acut
lung
injuri
suscept
patient
endotheli
dysfunct
eg
trauma
cardiac
surgeri
sepsi
also
develop
endorgan
dysfunct
part
multiorgan
system
failur
evolv
hemolyt
transfus
reaction
immedi
lifethreaten
delay
minim
result
clinic
consequ
eg
serolog
convers
current
estim
indic
wrong
unit
blood
administ
everi
u
transfus
u
involv
abo
incompat
catastroph
acut
hemolyt
transfus
reaction
htr
rare
ie
everi
u
everi
u
fatal
case
howev
account
least
ie
event
probabl
underreport
death
everi
year
ie
u
transfus
unit
state
base
transfus
million
unit
red
cell
annual
unit
state
approxim
nonfat
fatal
misidentif
error
year
contrast
death
total
death
relat
aboincompat
transfus
report
data
unit
kingdom
seriou
hazard
transfus
shot
reveal
error
transfus
result
major
morbid
death
report
also
reveal
event
multipl
error
process
error
occur
clinic
area
frequent
error
involv
failur
link
unit
patient
bedsid
catastroph
acut
htr
initi
sequenc
respons
includ
complement
hemostat
system
activ
neuroendocrin
respons
occur
predominantli
host
antibodi
attach
red
cell
antigen
incompat
donor
red
cell
gener
catastroph
acut
htr
involv
preform
igm
antibodi
abo
antigen
lead
hemolysi
mean
complement
fixat
format
immun
complex
littl
ml
aboincompat
blood
initi
symptom
consist
sever
acut
htr
fever
cytokinerel
hypotens
secondari
bradykinin
mast
cell
histamineserotonin
vasoact
amin
diffus
microvascular
bleed
secondari
hemostat
system
activ
dic
complementmedi
acut
intravascular
hemolysi
eg
acut
anemia
hemoglobinemiahemoglobinuria
acut
renal
insuffici
secondari
alphaadrenerg
vasoconstrict
deposit
antibodyco
stroma
within
renal
vasculatur
diagnosi
confirm
detect
free
hemoglobin
within
blood
urin
set
posit
direct
antiglobulin
test
dat
mixedfield
pattern
posttransfus
pretransfus
specimen
addit
test
order
includ
repeat
aborhesu
rh
test
unit
repeat
crossmatch
antibodi
detect
patient
preand
postreact
sampl
blood
unit
haptoglobin
ldh
serial
hemoglobinhematocrit
patient
specimen
examin
blood
remain
unit
hemolysi
treatment
gener
support
involv
resuscit
maintain
organ
perfus
use
volum
vasopressor
prefer
vasoconstrict
renal
bed
eg
low
dose
dopamin
mainten
good
renal
urin
output
mlh
hour
intraven
crystalloid
diuret
occas
transfus
support
hemostat
blood
product
set
dic
clinic
bleed
contrast
reaction
nonabo
antigen
involv
iggmedi
extravascular
clearanc
within
reticuloendotheli
system
re
often
delay
ie
day
detect
pretransfus
test
repres
anamnest
respons
except
pattern
kidd
antibodi
strong
complement
activ
result
acut
intravascular
htr
final
nonimmun
htr
also
occur
relat
temperatur
eg
overwarm
blood
warmer
use
microwav
oven
use
hypoton
solut
dilut
pack
red
blood
cell
prbc
mechan
issu
administr
ie
pressur
infus
pump
pressur
cuff
smallbor
needl
addit
normal
salin
use
dilut
red
cell
unit
calciumcontain
solut
avoid
unit
examin
larg
clot
transfus
cleric
misidentif
error
occur
everi
u
caus
immedi
immunemedi
htr
potenti
lethal
complic
prevent
dilig
confirm
patient
unit
identif
individu
initi
transfus
intraop
ie
anesthesiologist
circul
nurs
first
blood
bank
confirm
unit
identif
number
aborh
type
unit
blood
match
label
attach
unit
importantli
two
clinic
transfusionist
must
confirm
three
piec
patient
identif
eg
patient
name
hospit
identif
number
birth
date
social
secur
number
hospit
identif
band
surrog
eg
patient
name
plate
imprint
anesthesia
record
need
match
respect
paramet
unit
blood
obtain
thorough
understand
hemolyt
reaction
red
cell
antigen
system
serolog
diagnost
test
review
red
cell
antigen
system
includ
abo
relat
carbohydr
antigen
ie
h
p
lewi
blood
group
rh
system
antigen
includ
rhd
nonaborh
antigen
abo
carbohydr
rh
polypeptid
molecul
resid
surfac
red
blood
cell
us
popul
frequenc
distribut
b
ab
abo
molecul
express
specif
antigen
activ
individu
sugar
moieti
ad
short
sugar
chain
ie
oligosaccharid
sever
genet
determin
glycosyltransferas
enzym
abo
antigen
link
cell
ie
red
cell
cell
mean
associ
membranebound
protein
ie
glycoprotein
ceramid
residu
ie
glycosphingolipid
antibodi
b
antigen
gener
thought
form
result
exposur
sourc
antigen
ie
bacteria
first
month
life
blood
group
b
individu
produc
predominantli
igm
antibodi
ie
antib
antia
respect
wherea
blood
group
individu
produc
antib
antia
iggigm
antibodi
antibodi
lewi
antigen
gener
clinic
insignific
although
identifi
rh
antigen
five
princip
antigen
c
e
c
e
correspond
antibodi
account
clinic
issu
involv
rh
system
rh
system
antigen
nonglycosyl
fattyacyl
polypeptid
travers
red
cell
membran
time
although
individu
lack
antigen
form
antibodi
without
blood
exposur
antigen
highli
immunogen
individu
lack
antigen
form
antid
expos
transfus
lower
frequenc
approxim
pregnanc
nonaborh
glycoprotein
antigen
identifi
red
cell
antigen
also
express
cell
bodi
fluid
nonaborh
antigen
frequent
subdivid
common
ie
mn
kell
duffi
kidd
system
uncommon
antigen
system
eg
lutheran
diego
yt
xg
scianna
antibodi
common
antigen
caus
clinic
signific
immedi
delay
htr
usual
result
catastroph
complementmedi
hemolysi
although
occur
kidd
duffi
antibodi
sever
delay
htr
particularli
common
antikidd
antibodi
anoth
import
factor
rel
immunogen
ie
antibodi
format
vari
substanti
nonabo
antigen
eg
antid
antik
antifi
exposur
sever
blood
bank
procedur
type
screen
crossmatch
employ
routin
ensur
transfus
compat
blood
patient
abo
type
determin
use
direct
agglutin
red
cell
involv
use
forward
ie
use
patient
red
cell
antia
antib
reagent
revers
use
patient
sera
reagent
b
cell
type
forward
type
accur
newborn
infant
younger
month
base
transfer
matern
igg
molecul
lack
antia
antib
product
month
age
antibodi
screen
ie
indirect
antiglobulin
coomb
test
determin
whether
unexpect
antibodi
common
nonabo
red
cell
antigen
present
antibodi
found
gener
popul
hospit
patient
surgic
patient
antibodi
screen
perform
use
reagent
red
cell
ie
two
three
screen
cell
crosslink
antibodi
rabbitmous
antihuman
globulin
coomb
reagent
enhanc
iggmedi
agglutin
red
cell
sera
test
routin
antibodi
common
antigen
uncommon
nonabo
antigen
infrequ
ie
result
crossmatch
incompat
abo
compat
unit
set
neg
result
antibodi
screen
final
crossmatch
done
coomb
test
immedi
spin
crossmatch
electron
crossmatch
latter
two
procedur
simpli
confirm
abo
compat
donor
unit
requir
less
time
elect
procedur
type
screen
crossmatch
blood
request
never
commenc
antibodi
screen
determin
neg
set
posit
antibodi
screen
antibodi
crossmatch
compat
blood
identifi
avail
blood
sameday
urgent
surgeri
critic
import
understand
gener
applic
timet
import
neg
set
posit
male
rbc
gener
immedi
minut
avail
wherea
typespecif
rbc
avail
within
minut
receipt
patient
specimen
crossmatch
rbc
gener
avail
within
minut
mean
type
crossmatch
c
procedur
use
immedi
spin
crossmatch
done
antibodi
detect
antibodi
screen
posit
antibodi
screen
addit
time
sever
hour
even
day
may
requir
determin
antibodi
identifi
crossmatch
blood
antigenneg
event
antibodi
detect
screen
probabl
find
compat
unit
calcul
frequenc
antigen
preform
antibodi
eg
individu
antic
antifi
antibodi
compat
unit
blood
bank
accordingli
obtain
crossmatch
compat
blood
also
difficult
patient
antibodi
common
antigen
eg
k
case
unit
compat
clinician
also
may
face
inabl
obtain
crossmatch
compat
blood
patient
warm
autoantibodi
set
extens
serolog
analysi
use
absorpt
techniqu
requir
identifi
alloantibodi
altern
patient
transfus
recent
partial
phenotyp
determin
provid
antigenneg
red
cell
singledonor
apheresi
platelet
constitut
platelet
transfus
gener
avail
immedi
wherea
pool
platelet
concentr
may
take
minut
process
time
requir
obtain
plasma
cryoprecipit
vari
minut
minut
depend
whether
inventori
thaw
plasma
unit
maintain
avail
rapid
thaw
system
mild
urticari
symptom
eg
rash
hive
itch
occur
transfus
gener
selflimit
may
improv
prevent
antihistamin
prophylaxi
signific
allerg
transfus
reaction
occur
unit
like
relat
reaction
solubl
transfus
constitu
eg
complement
plasma
protein
drug
solubl
allergen
sever
anaphylact
reaction
occur
infrequ
ie
may
accompani
igemedi
symptom
involv
respiratori
eg
dyspnea
bronchospasm
gi
eg
nausea
diarrhea
cramp
circulatori
eg
arrhythmia
hypotens
syncop
system
iga
defici
occur
everi
patient
preform
antiiga
uncommon
caus
transfusionassoci
anaphylaxi
diagnosi
consid
patient
exhibit
anaphylaxi
potenti
caus
hemodynam
perturb
transfus
includ
citraterel
hypocalcemia
ie
rapid
infus
inadvert
intraven
air
embolu
particularli
autolog
blood
recoveri
reinfus
cytokinemedi
effect
bradykinin
activ
leukoreduct
filter
may
aggrav
inadequ
clearanc
patient
angiotensinconvert
enzym
inhibitor
report
fda
metabol
consequ
transfus
includ
coagulopathi
hypothermia
ie
inadequ
warm
refriger
prbc
unit
hyperkalemia
potassium
concentr
increas
storag
interv
prbc
unit
eg
meql
day
storag
approxim
meq
total
unit
prbc
addit
develop
alloantibodi
red
cell
antigen
sever
immunerel
phenomena
occur
subsequ
transfus
antigen
hla
system
determin
gene
major
histocompat
complex
short
arm
chromosom
hla
gene
product
cellsurfac
glycoprotein
cell
except
matur
red
cell
class
compris
hlaa
b
c
antigen
b
lymphocyt
cell
monocytemacrophag
lineag
class
ii
compris
hladr
dq
dp
gene
cluster
code
contribut
recognit
self
versu
nonself
import
respect
reject
transplant
tissu
longterm
surviv
solid
organ
bone
marrow
transplant
alloimmun
hla
antigen
occur
commonli
ie
time
transfus
multipar
patient
lead
immunemedi
platelet
refractori
ie
insignific
inadequ
rise
platelet
count
relat
dic
amphotericin
splenomegali
febril
nhtr
alloimmun
associ
develop
autoantibodi
lead
autoimmun
hemolyt
anemia
develop
posttransfus
purpura
ie
sever
thrombocytopenia
secondari
plateletspecif
antibodi
usual
antibodi
day
transfus
transfusionassoci
immun
system
modul
shown
benefici
effect
includ
improv
renal
allograft
surviv
reduc
risk
recurr
spontan
abort
reduc
sever
autoimmun
diseas
rheumatoid
arthriti
propos
detriment
effect
transfusionassoci
immun
system
modul
includ
increas
cancer
recurr
periop
infect
multiorgan
system
failur
overal
mortal
effect
controversi
transfus
howev
potenti
attenu
immun
respons
base
one
sever
potenti
mechan
includ
reduct
suppressor
cell
function
number
helper
cell
number
nk
cell
number
function
macrophag
number
function
mlc
respons
respons
mitogen
cellmedi
cytotox
although
sever
studi
demonstr
independ
effect
ie
use
multivari
statist
model
transfus
increas
periop
infect
ratesfour
five
time
numer
differ
surgic
popul
ie
trauma
hip
arthroplasti
spinal
colorect
cardiac
immunemodulatori
effect
transfus
incid
periop
infect
remain
controversi
addit
recent
metaanalysi
involv
review
peerreview
articl
patient
reveal
transfus
associ
periop
infect
odd
ratio
rang
accordingli
four
recent
studi
demonstr
administr
leukoreduc
unit
may
reduc
periop
infect
patient
undergo
either
colorect
gi
cardiac
surgeri
confirm
studi
howev
anoth
recent
retrospect
analysi
demonstr
reduct
periop
complic
mortal
leukoreduc
unit
use
rare
transfusionassoci
graftversushost
diseas
syndrom
manifest
sever
symptom
ie
fever
dermat
erythroderma
hepatitisenterocol
diarrhea
pancytopenia
hypocellular
bone
marrow
may
occur
secondari
transfus
cellular
blood
compon
contain
hlacompat
tlymphocyt
occur
frequent
transfus
relat
individu
prevent
standard
irradi
blood
product
sever
recent
studi
demonstr
transfus
associ
multiorgan
system
failur
mosf
periop
set
although
exact
mechan
potenti
effect
transfus
incid
complic
elucid
postul
patient
high
risk
eg
trauma
long
cpb
interv
develop
endotheli
dysfunct
either
white
cell
lytic
enzym
cellular
debri
injur
alreadi
dysfunct
endothelium
studi
also
demonstr
effect
impos
age
prbc
unit
load
effect
ie
direct
relationship
number
prbc
unit
administ
mosf
rate
preval
trali
expand
part
base
improv
report
potenti
overlap
diagnos
trali
versu
mosf
highrisk
patient
addit
recent
studi
van
de
water
demonstr
mortal
relat
mosf
reduc
patient
undergo
cardiac
surgeri
receiv
leukoreduc
prbc
unit
excess
bleed
requir
transfus
correct
anemia
hemostat
defect
also
may
result
complic
stroke
may
affect
longterm
mortal
larg
n
recent
publish
analysi
transfus
u
prbc
strongest
odd
ratio
independ
predictor
respect
periop
stroke
clear
analysi
whether
transfus
support
caus
factor
versu
predictor
anoth
recent
public
demonstr
strong
relationship
periop
platelet
transfus
stroke
death
support
anoth
recent
retrospect
analysi
demonstr
death
rate
larg
seri
patient
undergo
cardiac
surgeri
much
higher
patient
receiv
platelet
use
multivari
statist
model
accordingli
retrospect
analysi
demonstr
longterm
mortal
may
doubl
patient
receiv
transfus
retrospect
design
studi
definit
link
transfus
either
prbc
platelet
compon
stroke
increas
mortal
may
reflect
colinear
statist
passeng
effect
comorbid
excess
bleed
studi
howev
help
explain
agent
aprotinin
shown
reduc
blood
loss
transfus
reexplor
rate
sever
larg
random
placebocontrol
trial
also
associ
reduct
periop
stroke
reduc
mortal
whether
benefici
effect
agent
relat
reduct
incid
anemia
hypoperfus
relat
bleed
patient
also
receiv
multicompon
transfus
indirect
effect
agent
reduc
transfus
bleed
patient
concomit
reduct
transfusionrel
sequela
remain
unclear
iron
overload
ie
accumul
deposit
iron
within
vital
organ
occur
chronic
transfus
individu
patient
hemoglobinopathi
suscept
patient
emerg
techniqu
reduc
diseas
transmiss
hemolyt
transfus
reaction
activ
investig
implement
introduct
nucleic
acid
technolog
nat
test
procedur
minim
bloodborn
diseas
transmiss
detect
viral
rnadna
serolog
window
period
inactiv
viral
bacteri
rnadna
photochem
eg
psoralen
uvb
irradi
investig
techniqu
reduc
hemolyt
transfus
reaction
investig
convers
b
ab
red
cell
unit
mean
enzymat
digest
b
antigen
gener
ab
equival
plasma
mean
adsorpt
antia
antib
plasma
addit
new
patient
identif
system
eg
bar
code
identif
band
blood
bloodloc
safeti
system
novatek
medic
effingham
illinoi
implement
reduc
transfus
incompat
blood
part
base
recent
joint
commiss
accredit
healthcar
organ
highprior
direct
enhanc
patient
safeti
mean
improv
patient
identif
although
ongo
interfac
transfus
medicin
periop
servic
import
topic
review
briefli
transfus
medicin
servic
provid
assist
respect
patient
uniqu
clinic
problem
eg
patient
cold
agglutinin
diseas
use
special
blood
compon
implement
monitor
one
sever
nonpharmacolog
blood
conserv
strategi
preautolog
donat
normovolem
hemodilut
cell
salvag
techniqu
technic
blood
conserv
method
sever
pharmacolog
agent
eg
tranexam
acid
epsilon
amino
caproic
acid
aprotinin
use
reduc
bleed
transfus
cardiac
orthoped
liver
transplant
procedur
aprotinin
howev
agent
fdaapprov
patient
undergo
cardiac
revascular
also
agent
establish
efficaci
safeti
base
multipl
prospect
random
placebocontrol
trial
import
interact
transfus
medicin
periop
servic
includ
establish
monitor
standard
transfus
protocol
red
cell
hemostat
compon
emerg
offlabel
indic
factor
concentr
eg
factor
viia
import
blood
manag
strategi
although
sever
case
report
indic
offlabel
use
activ
factor
vii
revers
lifethreaten
bleed
cost
risk
thrombosi
preclud
routin
use
factor
concentr
potenti
lead
lifethreaten
thrombot
complic
subset
highrisk
patient
ie
patient
congenit
acquir
thrombot
disord
system
activ
hemostat
system
dic
cardiac
surgeri
larg
clinic
trial
evalu
efficaci
safeti
rfviia
need
widespread
use
recommend
use
pointofcar
laboratorybas
coagul
result
coupl
standard
approach
ie
algorithm
manag
bleed
cardiac
surgeri
shown
result
reduct
total
donor
exposur
one
eight
publish
studi
studi
also
demonstr
certain
patient
subgroup
may
benefit
offlabel
use
ddavp
respect
reduc
bleed
transfus
patient
type
von
willebrand
diseas
uremiainduc
platelet
dysfunct
platelet
defect
cardiac
surgeri
identifi
use
pointofcar
platelet
function
test
use
monitor
pointofcar
diagnost
guid
transfus
pharmacolog
manag
bleed
also
enhanc
mean
collabor
approach
transfus
medicin
servic
respect
implement
qualiti
control
monitor
regulatori
complianc
eg
joint
commiss
colleg
american
pathologist
futur
avail
blood
substitut
may
critic
uniqu
clinic
situat
patient
multipl
antibodi
jehovah
wit
patient
trauma
set
agent
also
may
enhanc
blood
conserv
techniqu
organ
preserv
abil
enhanc
tissu
oxygen
despit
improv
blood
screen
administr
techniqu
seriou
advers
event
relat
transfus
continu
occur
albeit
much
lower
incid
addit
develop
implement
new
screen
blood
purificationmodif
techniqu
incid
consequ
transfus
reaction
reduc
basic
understand
transfusionrel
complic
although
acut
hemolyt
transfus
reaction
transfusionassoci
anaphylaxi
sepsi
trali
occur
infrequ
dilig
administr
blood
monitor
develop
respect
signssymptom
minim
sever
potenti
lifethreaten
complic
addit
emerg
blood
bank
techniqu
psoralenuv
inactiv
pathogen
use
patient
identif
system
may
attenu
incid
advers
event
relat
transfus
respect
optim
blood
manag
mean
pharmacolog
nonpharmacolog
strategi
abil
reduc
use
blood
product
decreas
oper
time
reexplor
rate
import
implic
diseas
prevent
also
blood
inventori
cost
overal
health
care
cost
